Safety and efficacy of Palbociclib in combination with endocrine therapy in ER-positive HER2-negative advanced breast cancer-multi-institutional retrospective study -KBCOG-14

Safety and efficacy of Palbociclib in combination with endocrine therapy in ER-positive HER2-negative advanced breast cancer-multi-institutional retrospective study -KBCOG-14 - Safety and efficacy of Palbociclib in combination with endocrine therapy in ER-positive HER2-negative advanced breast cancer- KBCOG-14

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036224

Enrollment

200

Registered

2019-03-20

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ER-positive HER2-negative advanced breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)advanced/metastatic breast cancer patients 2)ER positive and/or PgR positive, HER2 negative in primary or metastatic lesion 3)treated by Palbociclib with endocrine therapy for more than 1 week between December in 2017 and December in 2018.

Exclusion criteria

Exclusion criteria: treated by Palbociclib with endocrine therapy for less than 1 week

Design outcomes

Primary

Measure	Time frame
PFS OS Adverse events	—

Countries

Japan

Contacts

Public ContactNina Odan

Shinko Hospital Breast Surgery

ni0214na@gmail.com078-261-6711

Outcome results